# Mama — activation-readiness audit after focused M3.1 R2

Status: **READY FOR EXPLICIT LIFECYCLE ACTIVATION GATE — not active yet**.

This audit consolidates:

- M3 core rules: `breast-0.1.2-m3-r2-reviewed-draft` — 15 rules, independent R2 approved, still draft;
- M3.1 under-40 scope: `breast-0.1.3-m3-1-under40-source-verified-draft`;
- M3.1 focused reviewed snapshot: `breast-0.1.6-m3-1-r2-reviewed-draft` — human gate + independent anonymous R2 approved, still draft;
- canonical Mama decision context: `breast-0.1.5-m3-1-decision-context-draft`;
- focused R2 approval record: `docs/v3/product/mama/20-phase-m3-1-r2-approval.md`.

## Readiness checks closed

- 15/15 M3 core rules have the governed R1 + independent R2 records and remain immutable/draft;
- all core rules have governed sourceRefs/locators;
- M3.1 under-40 semantics are source-backed for SUS, Brasil ampliado and USPSTF;
- the M3.1 final implementation received focused independent R2 approval;
- the R2 reviewer is represented only by the anonymous public handle `external-physician-r2-private-breast-001`;
- hard-exit precedence in people <40 is protected by automated safety cases;
- incomplete/unknown safety facts suppress routine age closure;
- SharedDecision reason semantics remain Mama-specific without Foundation expansion;
- the known-high-risk-familial input contract remains strict;
- a canonical Mama decision-context adapter consumes the engine result plus the M3.1 under-40 provenance artifact;
- Foundation remains unchanged;
- the Depth Budget remains shallow.

## Readiness verdict

`ready = true`

Remaining activation blockers tracked by this audit: **none**.

This means only that the clinical-content governance prerequisites represented by this audit are satisfied.

## Still NOT authorized

`ready = true` does **not** mean `active`.

No action in this readiness phase authorizes:

- lifecycle promotion to `active`;
- a canonical active Mama entrypoint;
- UI/product/report activation;
- merge;
- deploy;
- public release;
- real-world clinical use.

Lifecycle activation must occur only after a separate explicit approval from the project lead.

## Later product gates

These do not block clinical-content activation readiness, but remain necessary before product release:

- reassess provisional multi-source hard-exit provenance during Mama report/product integration;
- build Mama automation boundary/presentation;
- build progressive interview UI;
- integrate Report Foundation R3;
- perform real-browser accessibility/privacy/visual validation;
- preserve the same no-deep-diagnostic-tree Depth Budget.
